RNA M6A modification shaping cutaneous melanoma tumor microenvironment and predicting immunotherapy response

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Rising mortality rates in skin cutaneous melanoma (SKCM) persist despite immunotherapy advancements.
• Understanding RNA N6-methyladenosine (M6A) modifications is critical for SKCM prognosis, tumor microenvironment (TME) interactions, and predicting immunotherapy efficacy.

Purpose of the Study:

• To analyze the role of M6A regulators in SKCM.
• To identify M6A modification patterns associated with TME characteristics.
• To develop a predictive M6A score for patient outcomes and immunotherapy response.

Main Methods:

• Analysis of 23 M6A regulators in SKCM samples from TCGA and GEO databases.
• Principal Component Analysis (PCA) to derive an M6A score using gene expression and CNV data.
• Validation of the M6A score in anti-PD-1 and anti-PD-L1 therapy cohorts.

Main Results:

• Three distinct M6A modification patterns were identified, correlating with TME cell infiltration.
• The M6A score effectively predicted patient outcomes and response to immunotherapy.
• M6A modifications significantly influence SKCM progression, TME landscape, and tumor attributes.

Conclusions:

• M6A modification patterns are integral to SKCM development and progression.
• The M6A score serves as a robust, independent predictor of patient prognosis and immunotherapy response.
• Integrating M6A insights into clinical practice may transform SKCM management and treatment strategies.